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ABSTRACT
Introduction: Nonsteroidal anti-inflammatory drugs (NSAIDs) are
commonly used as part of multimodal analgesia in total knee
arthroplasty (TKA). Selective cyclooxygenase (COX)-2 inhibitors (e.g.,
celecoxib) are believed to have fewer gastrointestinal (GI) adverse
effects than nonselective NSAIDS. Meloxicam is less selective for COX2 than celecoxib is and partially inhibits COX-1 at higher doses.
Nonetheless, some surgeons prefer using nonselective NSAIDs
because of their lower expense.
Methods: Four thousand nine hundred ninety-four patients who
underwent TKA between January 2015 and February 2020 and took
either celecoxib (n = 3,174), meloxicam 15 mg/d (n = 1,819), or
meloxicam 7.5 mg/d (n = 451) were studied. Mutlimodal postoperative
analgesia protocols were otherwise similar. GI bleeding and wound
complication incidence were determined, as well as average 30-day
prescription costs.
Results: GI bleeding incidence was similar in the three cohorts (P =
0.4). The incidence of wound complications did not significantly differ
between the groups: 0.06%, 0.07%, and 0.22% in the celecoxib,
meloxicam 15 mg/d, and meloxicam 7.5 mg/d groups, respectively
(P = 0.06). Subsituting meloxicam for celecoxib results in an average
savings of $183 per prescription.
Discussion: Meloxicam used at higher doses (15 mg/d) does not
markedly increase the risk of GI or wound complications associated
with COX-1 inhibition and is less costly for multimodal analgesia after
TKA.
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otal knee arthroplasty (TKA) for the treatment of degenerative joint
disease provides patients with an improved quality of life and better
functional status; however, the procedure can result in moderate-tosevere postoperative pain.1 Historically, opioid medications have been the
cornerstone of postoperative analgesia after TKA, but our improved
-----
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After receiving exemption from our institutional review
board, we searched our institutional database to identify
patients who received a primary TKA between January

2015 and February 2020 who used celecoxib or meloxicam for postoperative analgesia. Because meloxicam
acts as a preferential COX-2 inhibitor at lower doses
and a nonselective NSAID at higher does, patients taking
meloxicam were further stratified into a 15 mg/d meloxicam cohort and 7.5 mg/d meloxicam cohort, and as
such, three cohorts of patients were analyzed.10 A total
of 4,994 patients were included in this study who
took either celecoxib (n = 3,174), meloxicam 15 mg/d
(n = 1,369), or meloxicam 7.5 mg/d (n = 451) for
postoperative TKA analgesia. Baseline characteristics
between the three groups were similar with the exception
of a slightly higher percentage of men in the celecoxib
cohort, slightly higher BMI in the meloxicam cohorts,
and lower CCI in the meloxicam 7.5 mg/d cohort
(Table 1); however, the age-adjusted CCI demonstrated
similarity among the three cohorts. Patients were either
prescribed meloxicam 7.5 mg/d, meloxicam 15 mg/d, or
celecoxib because of surgeon preference. Surgeons tended
to choose one medication and one dosage regimen and
did not switch over to another medication based on
perceived risk. Patient pain protocols were otherwise
similar among the three groups, and all patients were
prescribed with a proton-pump inhibitor as a part of the
standard of care at our institution. Patients who did not
fill their prescriptions or were found to not be taking the
prescription were excluded. After reviewing discharge
records and patient charts, a total of 4,994 patients were
included in the study.
The primary outcomes of our study were the incidence
of hematoma, generalized bleeding, gastrointestinal (GI)
bleeding, generalized wound complications, acute kidney injury, and manupulations under anesthesia. Generalized wound complications were defined to include
incidents of wound dehiscence (excluding those from
falls), wound drainage, incisional bleeding, and delayed
wound healing. Acute kidney injury was defined as an
abrupt decrease in glomerular filtration rate and increase
in creatinine and BUN. Our institutional nurse navigator
program that tracks postoperative complications was
queried to identify patients who developed any 90-day
complications. The implementation of our institutional
nurse navigator program has proven effective in detecting postoperative complications and even reducing the
episode of care costs after joint arthroplasty.11 Venous
thromboembolic event (VTE) prophylaxis chemical
agent use was also noted to control for any potential
source of confounding for postoperative complications.
Patients were recorded as taking either aspirin or nonaspirin (rivaraxoban, coumadin, enoxaparin, apixaban,
clopidegerol, or dabigatran). Aspirin, the agent that is
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understanding of pain physiology and transmission
helped to usher in the era of multimodal analgesia.2 The
premise of multimodal analgesia is to use nonnarcotic
medications such as acetaminophen, gabapentinoids,
and nonsteroidal anti-inflammatory drugs (NSAIDs),
among others, to reduce opioid-related adverse effects
while providing improved pain management.3 For
example, the tissue damage during TKA causes the
release of arachidonic acid, the precursor to prostaglandins, resulting in a hyperalgesiac response from the
peripheral nerves.1,4,5 Because NSAIDs block the conversion of arachidonic acid to prostaglandins, causing a
subsequent reduction in the hyperalgesiac response,
NSAIDs can be used to reduce postoperative pain as an
alternative to opioid medications.1,4,5
Nonsteroidal anti-inflammatory drugs are categorized based on their ability to selectively inhibit the cyclooxygenase (COX)-2 isoform that is responsible for the
production of prostiglandins. Nonselective NSAIDs (eg,
ibuprofen) provide relatively equivalent inhibition of the
COX-1 and COX-2 isoforms while selective COX-2
NSAIDs are subcategorized as highly selective (eg,
celecoxib) and preferentially selective (eg, meloxicam)
COX-2 NSAIDs.6 Although meloxicam does have a
preference for binding with COX-2, it also inhibits
COX-1 at the higher dosage regimens of 15 mg daily.7-9
Because COX-1 is constitutively expressed throughout
the body and plays a role in platelet function, protection
of gastric mucosa, and renal function, it resulted in the
development of the selective and preferentially selective
COX-2 NSAIDs with the intention to limit the negative
effect of COX-1 inhibition.5,9 Nevertheless, realizing the
full benefit of highly selective COX-2 inhibition while
avoiding the complications associated with COX-1
inhibition has not come to fruition.5
The purpose of this study was to compare the complication rates related to COX-1 inhibition between
those who receive either a nonselective (meloxicam
15 mg/d), preferential COX-2 (meloxicam 7.5 mg/d) or a
highly selective COX-2 (celecoxib) NSAID after primary
TKA and determine whether meloxicam, at a dose of
15 mg/d, is more cost-effective when considering the
potential cost of increased complications related to
COX-1 inhibition.

© American Academy of Orthopaedic Surgeons

Amer Haffar, BS, et al

Research Article

Table 1.

Summary of Patient Demographics
Celecoxib

Meloxicam 15 mg/d

Meloxicam 7.5 mg/d

Factor

N = 3,174

N = 1,369

N = 451

P

Age

65.0 (69.01)

64.5 (68.81)

65.1 (68.73)

0.2

Sex

0.01

Female

58.9%

63.3%

63.6%

Male

41.1%

36.7%

36.4%

BMI

30.8 (65.17)

31.1 (65.35)

31.3 (65.05)

0.04

CCI

0.69 (61.03)

0.74 (61.12)

0.58 (60.95)

0.03

Age adjusted CCI

2.74 (61.43)

2.77 (61.46)

2.65 (61.35)

0.4

Yes

0.62%

0.79%

0.49%

No

99.4%

99.2%

99.5%

History of chronic renal disease (CRD)

0.8

History of peptic ulcer disease (PUD)

1.0

Yes

0.2%

0.1%

0%

No

99.8%

99.9%

100%
,0.001

VTE prophylaxis drug
Aspirin

86.9%

86.0%

95.9%

Other

13.1%

14.0%

4.1%

VTE = thromboembolic event, BMI = Body Mass Index, CCI = Charlson Comorbidity Index
Values are reported in means and SD, with the exception of sex and VTE Prophylaxis. Bold P Values ,0.05 are deemed to be statistically
significant.

for continuous data, and chi-square testing was used for
categorical data. P values less than 0.05 was used to
determine significance. All statistical analyses were done
using R Studio (Version 3.6.3, Vienna, Austria).

Results
Patients in the three cohorts had similar incidences of renal
and peptic ulcer disease and were similar for GI and renal
risk (Table 1). Aspirin BID usage for VTE prophylaxis was
96% in the meloxicam 7.5 mg/d cohort, 86% in the meloxicam 15 mg/d cohort, and 87% in the celecoxib cohort
(P , 0.001). No statistical difference in complication rates
were found between the three cohorts (Table 2).

Discussion
A large impediment to the wider adoption of oral
NSAIDs for postoperative primary TKA analgesia are
concerns regarding the GI and renal adverse effects
associated with COX-1 inhibition from nonselective
NSAIDs, especially with the increased utilization of
postoperative IV ketorolac, IV corticosteroids, and VTE
prophylaxis of aspirin.9 Currently, limited evidence is
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most commonly used at our institution for VTE
prophylaxis, is an irreversible COX-1 inhibitor,12 hindering platelet synthesis and potentially compromising
gastorintestinal and renal health. Patients were deemed to
be nonaspirin users if they were found to be taking either
rivaraxoban, coumadin, enoxaparin, apixaban, clopidegerol, or dabigatran and were analyzed together. Medications such as factor Xa and direct thrombin inhibitors
may be associated with increased bleeding and wound
complication rates13 while aspirin may limit wound
complications and bleeding.14,15 Average retail prices
for a 30-day supply of 15 mg of meloxicam ($32.99) and
200 mg of celecoxib ($215.99), as of February 2021,
were obtained using www.WebMD.com/rx/drug-prices.
Informal cost analysis was done by comparing the
average retail price of a 30-day supply of 15 mg of meloxicam and 200 mg of celecoxib, the two most commonly prescribed dosages for those medications at our
institution, to calculate the savings associated with
substituting meloxicam 15 mg/d for celecoxib 200 mg/d
in postoperative TJA pain protocols. Continuous data are
presented as mean (SD), and categorical data are presented as cell count (percent of total count). T-tests or
analysis of variance tests were used to calculate P values
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Table 2.

Summary of the Complication Data for Our Study
Celecoxib

Meloxicam 15 mg/d

Meloxicam 7.5 mg/d

P

Hematoma

6 (0.19%)

1 (0.07%)

0 (0.00%)

0.8

Generalized bleeding

2 (0.06%)

1 (0.07%)

0 (0.00%)

1.0

GI bleeding/ulceration

2 (0.06%)

1 (0.07%)

1 (0.22%)

0.4

Generalized wound complications

18 (0.57%)

5 (0.37%)

3 (0.67%)

0.6

0 (0%)

0 (0%)

0 (0%)

1.0

190 (5.99%)

76 (5.55%)

22 (4.88%)

0.6

Acute kidney injury
Manupulations under anesthesia
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available regarding the safety profile of nonselective
NSAIDs after discharge from primary TJA. In light of
the opioid epidemic, a working committee of the
American Association of Hip and Knee Surgeons,
American Academy of Orthopaedic Surgeons Hip
Society, Knee Society, and the American Society of
Regional Anesthesia and Pain Medicine have suggested
that the safety of nonselective NSAIDs after primary
TKA be investigated.16
Therefore, we sought to investigate for any potential
differences in COX-1 inhibition-related postoperative
complications between nonselective NSAID dosing of
meloxicam, preferential COX-2 NSAID dosing of meloxicam, or highly selective COX-2 NSAID dosing of
celecoxib. Our findings suggest that using meloxicam at
either a nonselective (15 mg/d) or preferential COX-2
(7.5 mg/d) dose as a part of a postoperative multimodal
TKA pain protocol does not seem to result in an increased
incidence of postoperative GI bleeding compared with
the usage of celecoxib, P = 0.4, considering that patients
in the three cohorts had similar GI risk profiles: 0.2%,
0.1%, and 0% of patients in the celecoxib, meloxicam
15 mg/d, and meloxicam 7.5 mg/d cohorts had a history
of peptic ulcer disease (P = 1.0). These findings did not
agree with our hypothesis because we expected patients
on meloxicam, particularly when consuming 15 mg/d,
to have a greater incidence of GI bleeding and ulceration
based on meloxicam being a nonselective NSAID at
higher doses.
Currently, there is a paucity of data comparing the
incidence of GI complications between selective COX-2,
preferential COX-2, and nonselective NSAIDs with
inconsistency in the reported literature. A study of the
general population in England showed that the usage of
meloxicam compared with celecoxib resulted in an
increased incidence of GI complications.17 After adjustment for age, sex, medical history of upper GI complications, and NSAID usage within 3 months of the study
period, celecoxib was found to result in a relative rate

reduction in symptomatic GI events and upper GI
complications.17 In the realm of joint arthroplasty
analgesia, a high-quality clinical trial showed that a
nonselective NSAID (lornoxicam) resulted in a higher
incidence of symptomatic GI complications than a
selective COX-2 NSAID,18 but did not reach statistical
significance. Although we only reported clinical GI
complications, and not symptomatic GI complications,
there seems to be an agreement with the findings of our
study. The results of our study also agreed with that of
Rawal et al19 because their results suggested that there
was no increased incidence of adverse GI events
between a selective COX-2 NSAID, etoricoxib, and
nonselective NSAID, ibuprofen. Nevertheless, because
of the rarity of upper GI complications associated with
NSAIDS,16 clinical trials may not report this extensively
and may be underpowered.
The incidence of hematoma and generalized bleeding
was found to be equivalent among patients in the three
cohorts, P = 0.8, and P = 1.0, respectively. Limited data
are currently available to suggest whether nonselective
NSAIDS are inferior to selective COX-2 NSAIDs for
postoperative bleeding after primary TJA. Nevertheless,
our findings agree with those of another clinical trial,19
which showed that there was no difference among patients in the treatment groups comparing etoricoxib,
ibuprofen, and placebo for the incidence of postoperative bleeding events after TKA. Patients in that study
received the intervention for 7 days postoperatively and
were not on any medication for VTE prophylaxis. Their
results were underpowered to determine bleeding risk
and should be interpreted with caution.
We report no incidents of acute kidney injury among
our patients (P = 1.0). These results are promising
because we had a relatively large patient cohort compared with previous clinical trials and that patients in
the three cohorts were similar for renal risk (P = 0.8), we
support conducting additional studies to determine
whether nonselective NSAIDs result in an increased
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Conclusion
Although the importance of a patient’s medical history
has been stressed when prescribing NSAIDS, particularly higher doses of meloxicam, it has an equivalent
safety profile to celecoxib after primary TKA. Meloxicam usage, particularly at higher doses does not seem to
increase the risk of complications potentially related to
COX-1 inhibition. Therefore, meloxicam may be
considered a safe and low cost alternative to celecoxib
for TJA postoperative analgesia.
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7.5 mg/d cohorts, respectively, had a prior history of
peptic ulcer disease (P = 1.0), suggesting that patients in
our study had low GI risk in general. Furthermore, our
institutional guidelines limit the prescription of NSAIDS
to patients with serious GI risk. Therefore, we believe that
these variables, taken together, should not detract from
the findings of our study and that these results offer the
best available evidence on NSAIDS and postoperative
complications in TKA. We would encourage prospective
studies to corroborate our findings. We also could not
evaluate the analgesic effectiveness of the medications
used at various dosages. Nevertheless, clinical practice
guidelines dictate that irrespective of COX-1/COX-2
selectivity, there is no difference in analgesic effectiveness
among NSAIDs.18,19,22 Although we used average retail
costs, in practice, the cost of prescriptions may vary
depending on insurance coverage, rebate, and discount
programs at pharmacies. The strengths of our study
include having the largest retrospective comparative
study of the safety profile of NSAIDS in the realm of TJA
and having a large cohort size of patients, showing that
our results have external validity.
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incidence of acute kidney injury. There may be a possibility
that a larger patient population may be needed to determine any differences for this rare yet clinically devastating
event. Currently, there are no high and moderate quality
clinical trials that compare the incidence of acute kidney
injury between selective COX-2 NSAIDs and nonselective
NSAIDS in the realm of joint arthroplasty.9 In one systematic review and meta-analysis, meloxicam was found
to result in an increased risk of acute renal failure compared with nonusers; however, these results did not reach
statistical significance and this may be attributed to small
sample size.20 Celecoxib was found to impart an increased
risk of acute renal failure compared with nonusers;
however, this did not approach statistical significance as
well.20 Nevertheless, just like our study, Ungprasert et al20
did not find any difference in the overall risk for developing acute renal injury.
With our findings suggesting no difference in the
incidence of postoperative complications among patients
using low-dose meloxicam (7.5 mg/d), high-dose meloxicam (15 mg/d), and celecoxib, formal cost-analysis
was not done because it is evident that meloxicam usage
would demonstrate cost-savings. Using the values of the
average retail medication prices in 2020, we found the
cost for a 30-day supply of 15 mg of meloxicam to be
$32.99, whereas the cost of a 30-day supply of 200 mg of
celecoxib to be $215.99. If patients were to use 15 mg
meloxicam daily for postoperative TKA analgesia rather
than 200 mg celecoxib daily, this would result in a saving
of $183 per prescription on average. Based on the finding
that 9% of the patients were prescribed celecoxib for
postoperative pain control at our institution, if this figure
were to be applied to the TKA population in the United
States, approximately 700,000, prescribing meloxicam
in place of celecoxib would generate a savings of $12
million to the healthcare system.
Our study contains all the weaknesses that are present
in retrospective reviews. Because we established cohorts
based on what TKA patients were prescribed, the retrospective nature of the study means that patients who were
prescribed may not have been taking celecoxib or meloxicam as instructed. Nonetheless, we reviewed the
discharge medications of those who had a discharge
record present in our system and whether celecoxib or
meloxicam use was mentioned in patient chart note
search to improve the accuracy of our data. About our
primary end point, GI bleeding/ulceration, we were
underpowered because of the low incidence of these
complications in our cohort. The low incidence of GI
complications and thus the underpowered findings may
be attributable to the rarity of the complication.16 At our
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